Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3431-3440 Newer>

BusinessWeek February 5, 2007	The Doctor Won't See You Now A host of forces is now converging to clamp down on hard-driving, gift-toting pharmaceutical pitchmasters who have been ambushing physicians for the last decade.
BusinessWeek February 5, 2007 Amy Barrett	Andersen Was Never This Rewarding Ex-CEO Berardino is improbably recast as an AIDS fighter at biotech startup Profectus.
BusinessWeek February 5, 2007 Catherine Arnst	Keeping Lawyers Out Of The Lab Researchers gripe that suits arising from their findings waste time and hurt their reputations.
BusinessWeek February 5, 2007 Richard S. Dunham	Health-Care Reform Is In The Air, But... Despite all the big talk and odd alliances, expect only small steps for now in health-care reform.
The Motley Fool January 25, 2007 Brian Lawler	Discovery Finds Its Way Even though Discovery Laboratories has been in control of its manufacturing plant for only one of the approvable letters, another failure to get approval of Surfaxin will probably be strike three for most investors.
The Motley Fool January 25, 2007 Brian Lawler	Renovis Tries to Right Itself Renovis takes some steps to try and recover after its lead drug fails in clinical testing. Investors, take note.
The Motley Fool January 24, 2007 Brian Lawler	Neurocrine in the Green 2006 wasn't kind to the drug developer, but whatever happens with indiplon, Neurocrine's management deserves kudos for keeping investors well informed on the status of the drug and where the company stands as far as timelines go.
The Motley Fool January 23, 2007 Seth Jayson	'Tis the Season Chinese medical device maker Mindray Medical $309 million offering looks to be all insider selling. Investors, take note.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool January 23, 2007 Ralph Casale	Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note.
<Older 3431-3440 Newer> Return to current articles.